- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00930033
Clinical Trial to Assess the Importance of Nephrectomy (CARMENA)
Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The 2 previous studies on the impact of nephrectomy (EORTC, SWOG) in metastatic renal cell carcinoma have justified recommendation to initial nephrectomy for patients presenting with metastatic renal cell carcinoma. But these studies were performed at the time of immunotherapy.
The objective is Evaluation of the importance of nephrectomy in patients with metastatic renal cell carcinoma treated with sunitinib (AA) Arm A : Nephrectomy followed by Sunitinib Arm B : Sunitinib alone Sunitinib will be administrated orally daily for 4 weeks followed by a 2 week rest( schedule 4/2), 6 weeks are considered as a cycle The starting dose will be 50 mg daily with provision for dose reduction based on tolerability Patient will be treated until disease progression or unacceptable toxicity occurrence or withdraw.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Paris, France, 75015
- Hôpital Necker
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- age ≥ 18 years
- ECOG Performance Status 0 - 1
- Biopsy (primary tumour or metastases) confirming the diagnosis of clear cell carcinoma
- Documented metastatic disease
- Absence of prior systemic treatment for kidney cancer including AA
- Tumour amenable to nephrectomy (partial or total) in the opinion of the patient's urologist. Patients presenting with an inferior vena cava thrombosis can be included.
- Patients for which the indication of Sunitinib is considered according to the recommendations rules given by national health authorities of participating countries. The prescription of Sunitinib in the circumstances of the study is considered as a standard treatment.
- Platelets > or = 100 x 109/L, haemoglobin >or = 9 g/dl, neutrophils >or = 1.5 x 109/L;
- Bilirubin < or = 2 mg/dL, aspartate transaminase (ASAT) and alanine transaminase (ALAT)< or = 2.5 times the upper normal limit (UNL) or < or = 5 times UNL for patients with liver metastases
- Patients of child bearing age should use contraceptive methods
- Patient able to follow the procedures outlined in the protocol as far as the planning of visits and examinations are concerned.
- Life expectancy ≥ 3 months
- Written informed consent
- Patient without brain metastases or with radiotherapy or surgery treated brain metastases without progression into 6 weeks and non treated by corticoid
- Patient non treated by anticoagulants excepted HBPM
Exclusion Criteria:
- Prior systemic treatment for kidney cancer (including Anti Angiogenic)
- Bilateral kidney cancer
- Pregnant or breast feeding women
- Acute coronary syndrome or episode of myocardial infarction or severe or unstable angina within the last 6 months as well as severe diabetes with severe peripheral arteriopathy or deep phlebitis not treated with low molecular weight heparin or arterial thrombosis within the last 3 months
- Patients being treated with antivitamin K with curative intent (please note that patients being treated with low molecular weight heparin can be included)
- Medical, general or psychiatric difficulties which, in the opinion of the Investigator, would make it inappropriate for trial entry
- Symptomatic or untreated brain metastases (patients with brain metastases that have been treated by radiotherapy or surgery and have stable disease within 6 weeks, and are not requiring treatment with corticosteroids can be included)
- Previous history of gastric disease or malabsorption, syndrome compromising the absorption of Sunitinib
- Experimental treatment within the 28 days preceding inclusion
- Other cancer within the previous 5 years (except for insitu skin carcinoma and treated localised prostate cancer with undetectable PSA)
- Patient has received treatment with IV biphosphonate
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur actif: A
Nephrectomy + sunitinib
|
Current surgery
|
Expérimental: B
Sunitinib alone
|
Sunitinib alone without nephrectomy
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
The primary endpoint is overall survival.
Délai: starting at 4 months
|
starting at 4 months
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Objective Response (complete or partial) is evaluated according to RECIST 1.1 criteria
Délai: Starting at 4 months
|
Starting at 4 months
|
Clinical benefit (complete response, partial or stable for at least 12 weeks).
Délai: Starting at 4 months
|
Starting at 4 months
|
Progression-Free Survival
Délai: Starting at 4 months
|
Starting at 4 months
|
Non-compliance to Sunitinib treatment is evaluated in arm A (nephrectomy + sunitinib) as the percentage of patients not starting sunitinib treatment within 6 weeks after nephrectomy
Délai: Starting at 4 months
|
Starting at 4 months
|
Non-compliance to sunitinib treatment is evaluated in arm B (sunitinib alone) as the percentage of patients needing nephrectomy
Délai: Starting at 4 months
|
Starting at 4 months
|
Post operative morbidity is evaluated as the percentage of deaths within 30 days following nephrectomy
Délai: Starting at 4 months
|
Starting at 4 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Arnaud Mejean, MD PhD, Assistance Publique - Hôpitaux de Paris
Publications et liens utiles
Publications générales
- Mejean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.
- Leon L, Garcia-Figueiras R, Suarez C, Arjonilla A, Puente J, Vargas B, Mendez Vidal MJ, Sebastia C. Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. Target Oncol. 2014 Mar;9(1):9-24. doi: 10.1007/s11523-013-0304-7. Epub 2013 Dec 12. Erratum In: Target Oncol. 2014 Jun;9(2):181. Garcia-Figueras, Roberto [corrected to Garcia-Figueiras, Roberto].
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par type histologique
- Tumeurs
- Tumeurs urologiques
- Tumeurs urogénitales
- Tumeurs par site
- Maladies rénales
- Maladies urologiques
- Adénocarcinome
- Tumeurs, glandulaires et épithéliales
- Tumeurs rénales
- Carcinome à cellules rénales
- Carcinome
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Inhibiteurs de l'angiogenèse
- Agents modulateurs de l'angiogenèse
- Substances de croissance
- Inhibiteurs de croissance
- Inhibiteurs de protéine kinase
- Sunitinib
Autres numéros d'identification d'étude
- P070144
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .